CA2272243A1 - Novel low density lipoprotein binding proteins and their use in diagnosing and treating atherosclerosis - Google Patents

Novel low density lipoprotein binding proteins and their use in diagnosing and treating atherosclerosis Download PDF

Info

Publication number
CA2272243A1
CA2272243A1 CA002272243A CA2272243A CA2272243A1 CA 2272243 A1 CA2272243 A1 CA 2272243A1 CA 002272243 A CA002272243 A CA 002272243A CA 2272243 A CA2272243 A CA 2272243A CA 2272243 A1 CA2272243 A1 CA 2272243A1
Authority
CA
Canada
Prior art keywords
lbp
seq
polypeptide
agent
glu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002272243A
Other languages
English (en)
French (fr)
Inventor
Ann M. Lees
Robert S. Lees
Simon W. Law
Anibal A. Arjona
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston Heart Foundation Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2272243A1 publication Critical patent/CA2272243A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/0004Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/04Endocrine or metabolic disorders
    • G01N2800/044Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/32Cardiovascular disorders
    • G01N2800/323Arteriosclerosis, Stenosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
CA002272243A 1996-11-27 1997-11-26 Novel low density lipoprotein binding proteins and their use in diagnosing and treating atherosclerosis Abandoned CA2272243A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US3193096P 1996-11-27 1996-11-27
US60/031,930 1996-11-27
US4854797P 1997-06-03 1997-06-03
US60/048,547 1997-06-03
PCT/US1997/021857 WO1998023282A1 (en) 1996-11-27 1997-11-26 Novel low density lipoprotein binding proteins and their use in diagnosing and treating atherosclerosis

Publications (1)

Publication Number Publication Date
CA2272243A1 true CA2272243A1 (en) 1998-06-04

Family

ID=26707786

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002272243A Abandoned CA2272243A1 (en) 1996-11-27 1997-11-26 Novel low density lipoprotein binding proteins and their use in diagnosing and treating atherosclerosis

Country Status (10)

Country Link
US (2) US6355451B1 (ja)
EP (1) EP0969855B1 (ja)
JP (1) JP4184437B2 (ja)
AT (1) ATE317264T1 (ja)
AU (1) AU736142B2 (ja)
CA (1) CA2272243A1 (ja)
DE (1) DE69735243T2 (ja)
ES (1) ES2258798T3 (ja)
IL (1) IL129910A0 (ja)
WO (1) WO1998023282A1 (ja)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6605588B1 (en) 1996-11-27 2003-08-12 Boston Heart Foundation, Inc. Low density lipoprotein binding proteins and their use in diagnosing and treating atherosclerosis
US6632923B1 (en) 1996-11-27 2003-10-14 Boston Heart Foundation, Inc. Low density lipoprotein binding proteins and their use in diagnosing and treating atherosclerosis
JP2004536082A (ja) * 1999-10-22 2004-12-02 グラクソ グループ リミテッド invivoイメージング
CN1329142A (zh) * 2000-06-21 2002-01-02 上海博德基因开发有限公司 一种新的多肽——rna聚合酶ii相关蛋白11.33和编码这种多肽的多核苷酸
US20050154407A1 (en) * 2000-12-20 2005-07-14 Fox Hollow Technologies, Inc. Method of evaluating drug efficacy for treating atherosclerosis
US20060032508A1 (en) * 2000-12-20 2006-02-16 Fox Hollow Technologies, Inc. Method of evaluating a treatment for vascular disease
US7794413B2 (en) * 2005-04-19 2010-09-14 Ev3, Inc. Libraries and data structures of materials removed by debulking catheters
WO2009154025A1 (ja) 2008-06-20 2009-12-23 国立大学法人岡山大学 酸化LDL/β2GPI複合体に対する抗体及びその用途
IN2014DN09963A (ja) * 2012-06-06 2015-08-14 Inst Nat Sante Rech Med

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59206046A (ja) 1983-05-11 1984-11-21 Asahi Chem Ind Co Ltd 低比重リポ蛋白質を吸着する材料
US4660563A (en) 1984-12-31 1987-04-28 Massachusetts Institute Of Technology Method and means for detection of arterial lesions
US4877599A (en) 1986-11-10 1989-10-31 New England Deaconess Hospital Corporation Detection of vascular disease with labelled antibodies
US5726153A (en) 1988-05-02 1998-03-10 New England Deaconess Hospital Corporation Synthetic peptides for arterial imaging
US5135848A (en) 1989-10-23 1992-08-04 Lehigh University And Northeast Benjamin Franklin Technology Center Of Pa Methods for evaluating cholesterol metabolism and reagents therefor
US5196324A (en) 1989-12-15 1993-03-23 Eli Lilly And Company Monoclonal antibodies reactive with a human atheroma associated antigen
AU663291B2 (en) 1990-05-03 1995-10-05 New England Deaconess Hospital Corporation Synthetic peptides for arterial imaging
DE4222385A1 (de) 1992-07-08 1994-01-13 Boehringer Ingelheim Int Verfahren zur Isolierung von Inhibitoren des Rhinovirus-Rezeptors
EP0586094A1 (en) 1992-08-03 1994-03-09 Wisconsin Alumni Research Foundation Soluble LDL receptor and gene
AU6234194A (en) 1993-01-15 1994-08-15 Board Of Regents, The University Of Texas System High molecular weight b-cell growth factor: interleukin-14
JPH09163988A (ja) 1995-10-09 1997-06-24 Kowa Co 新規なldl受容体類似蛋白質及び遺伝子

Also Published As

Publication number Publication date
EP0969855A1 (en) 2000-01-12
JP2001506983A (ja) 2001-05-29
ES2258798T3 (es) 2006-09-01
WO1998023282A1 (en) 1998-06-04
US6355451B1 (en) 2002-03-12
EP0969855B1 (en) 2006-02-08
AU736142B2 (en) 2001-07-26
ATE317264T1 (de) 2006-02-15
AU7408898A (en) 1998-06-22
JP4184437B2 (ja) 2008-11-19
DE69735243D1 (de) 2006-04-20
DE69735243T2 (de) 2006-11-02
IL129910A0 (en) 2000-02-29
US20020052033A1 (en) 2002-05-02
EP0969855A4 (en) 2001-08-16

Similar Documents

Publication Publication Date Title
US7807384B2 (en) Low density lipoprotein binding proteins and their use in diagnosing and treating atherosclerosis
US6605588B1 (en) Low density lipoprotein binding proteins and their use in diagnosing and treating atherosclerosis
US20080051338A1 (en) 98 Human Secreted Proteins
US20030065151A1 (en) Secreted protein HCEJQ69
US6322976B1 (en) Compositions and methods of disease diagnosis and therapy
US20040253684A1 (en) 47 human secreted proteins
US6534631B1 (en) Secreted protein HT5GJ57
US20040048294A1 (en) 31 human secreted proteins
CA2272243A1 (en) Novel low density lipoprotein binding proteins and their use in diagnosing and treating atherosclerosis
WO1998008381A1 (en) Therapeutic and diagnostic applications of perlecan domain i splice variants
US6844170B1 (en) Cytokine receptor common gamma chain like
CA2392472A1 (en) Use of disease-associated gene
US20010016647A1 (en) 29 human secreted proteins
JP2003525599A (ja) 肺癌特異的遺伝子による肺癌の診断、モニタリング、病期分類、イメージングおよび治療の方法
US20030065139A1 (en) Secreted protein hmmbd35
WO2003033672A2 (en) Nr3b nmda receptor subunit compositions and related methods
AU769970B2 (en) Novel low density lipoprotein binding proteins and their use in diagnosing and treating atherosclerosis
US20030152933A1 (en) Human secreted proteins
CA2350785A1 (en) 31 human secreted proteins
US20020026037A1 (en) Vascular endothelial growth factor 3 antibodies
JP4147058B2 (ja) 精神分裂病診断剤
JPH11185A (ja) Atg−1120(aif−1−デルタ)、aif−1/rc−9の新規スプライス変種

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued